▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3782 by analyst upside · 2026-11-13
RPRX
Royalty Pharma plc
Healthcare · Market Cap $40B · P/E 45.1x
ANALYST PRICE TARGET
+4.4%
implied upside to consensus target
Current Price $68.97
Consensus Target $72.0
Bull Target $78.0
Bear Target $66.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
2
Sell
0
52-Week Low $37.31
52-Week High $70.37
YTD Return +79.9%
FUNDAMENTALS
Market Cap $40B
P/E Ratio (TTM) 45.1x
Forward P/E 11.7x
EPS (TTM) $1.53
PEG Ratio 2.12
Dividend Yield 1.36%
Revenue (TTM) $2.6B
Profit Margin 25.7%
52-WEEK RANGE
52-Week Low $37.31
52-Week High $70.37
Current Price $68.97
Bear Target $66.0
Bull Target $78.0
● Now $68.97 ● Target $72.0
TRADING DATA
Avg Volume 3.1M
YTD Return +79.9%
Analyst Count 8
Consensus Buy
Upside to Target +4.4%
Last Updated 2026-11-13

ANALYST SUMMARY

Royalty Pharma plc (RPRX) is currently trading at $68.97 with a Wall Street consensus price target of $72.0, implying potential upside of 4.4% over the next 12 months. 8 analysts currently cover RPRX, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $78.0, while the most cautious has a target of $66.0.

RPRX operates in the Healthcare sector with a market capitalisation of $40B. The stock is up 79.9% year-to-date and is currently trading near the upper end of its 52-week range of $37.31 – $70.37.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RPRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-11-05 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-10-07 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-09-08 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-07 43% win rate (7 calls)
TD Cowen - Reiterated
Buy → Buy 2026-07-13 Building track record
Citigroup - Reiterated
Buy → Buy 2026-05-07 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-05-07 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-04-21 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
17/30
Consensus clarity
27/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →